Key clinical point: About 40% of all patients with psoriatic arthritis who start a first TNF inhibitor continue to have an unacceptable level of pain at 1 year.
Major finding: The fraction of patients who had unacceptable pain despite inflammation control was largely unchanged over the study period (24% at treatment start, 27% at 3 months, and 26% at 12 months).
Study details: A prospective study of 352 Swedish patients with psoriatic arthritis who started a first anti-TNF therapy during 2004-2010.
Disclosures: Dr. Olofsson had no financial conflicts to disclose. Two of his coauthors reported relationships with AbbVie, Eli Lilly, Celgene, Novartis, UCB, and Sandoz.
Roseman C et al. Ann Rheum Dis. 2019 Jun;78(Suppl 2):129-30. Abstract OP0112, doi: 10.1136/annrheumdis-2019-eular.1839.